BMY - Bristol-Myers Squibb Company
| Previous Close | 58.90 |
| Open | 57.83 |
| Bid | 59.00 x 800 |
| Ask | 59.13 x 900 |
| Day's Range | 58.81 - 59.08 |
| 52 Week Range | 42.48 - 59.18 |
| Volume | 947,595 |
| Avg. Volume | 15,844,904 |
| Market Cap | 138.489B |
| Beta (3Y Monthly) | 0.69 |
| PE Ratio (TTM) | 17.07 |
| EPS (TTM) | 3.46 |
| Earnings Date | Jan 22, 2020 - Jan 27, 2020 |
| Forward Dividend & Yield | 1.64 (2.84%) |
| Ex-Dividend Date | 2019-10-03 |
| 1y Target Est | 64.70 |
- Zacks
Want To Retire Early? Learn the Intelligent Investing Secret - December 05, 2019
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
- GuruFocus.com
Bayer and Teva Double Down on Worst M&A Deals of Decade
The companies both hit the dubious roster twice, but are joined by many of the biggest names in the drug industry Continue reading...
- Zacks
Is Bristol-Myers Squibb (BMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
- Zacks
Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC
Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.
- Zacks
5 High-Flying Stocks Near 52-Week High With More Room to Run
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
- Investor's Business Daily
Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?
- Investor's Business Daily
Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?
- Simply Wall St.
Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY)
Does the December share price for Bristol-Myers Squibb Company (NYSE:BMY) reflect what it's really worth? Today, we...
- Business Wire
Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant
Bristol-Myers Squibb Company (BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors. Stem cell transplants have been shown to be an effective treatment for aggressive leukemias and other hematological malignancies, often representing the only therapeutic option for cure. “While ideally we prefer using fully matched transplants from a sibling for the treatment of hematologic cancers, only the minority of patients have such a sibling,” said study lead investigator Leslie Kean, M.D., Director of the Stem Cell Transplantation Program, Dana Farber/Boston Children’s Cancer and Blood Disorders Center.
- Zacks
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)
Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).
- Zacks
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
- Zacks
Top Ranked Income Stocks to Buy for December 3rd
Top Ranked Income Stocks to Buy for December 3rd
- Business Wire
Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for the use of Reblozyl® (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at its meeting on December 18, 2019. Bristol-Myers Squibb is seeking approval of Reblozyl, an erythroid maturation agent representing a new class of therapy, for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
- Zacks
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY) closed at $57.41 in the latest trading session, marking a +0.83% move from the prior day.
- InvestorPlace
4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY
Markets were hit hard in early Monday trading, as trade tensions spooked investors. Let's look at a few top stock trades as we enter the last trading month of 2019. Top Stock Trades for Tomorrow No. 1: Roku (ROKU)Source: Chart courtesy of StockCharts.comRoku (NASDAQ:ROKU) was down around 7% in pre-market trading thanks to a negative analyst note from Morgan Stanley. At 8 a.m. ET, not many were expecting the stock to be down 17% a few hours later.But that's exactly what we had, before shares erased some of those gains. While Roku was hammered on a day where the rest of the market was under pressure too, a 17% beating is not really a fair response given that nothing actually changed with the company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo how do we trade it?The decline all but solidified $170 as resistance, but support came into play where it needed to. The 50-day moving average is near $132, while the 100-day is at $130. Not many expected Roku to go from $160 to $132-and-change in one day, but with Monday's bounce, support is doing its job. * 7 Entertainment Stocks to Buy to Escape Holiday Blues Below $130, though, the $116 to $120 area could be in the cards. Otherwise, let's see if Roku can fill some of this gap. Top Stock Trades for Tomorrow No. 2: Gogo (GOGO)Source: Chart courtesy of StockCharts.comOn tough market days, I love to look for the stocks showing relative strength. Unlike many in the market, Gogo (NASDAQ:GOGO) was positive throughout the session.On Friday, the 200-day moving average held as support, along with channel support (blue line). On Monday, the stock reclaimed the 100-day moving average. Now, bulls need to see the stock hold the $5.25 level and continue higher.If it does, look to see if Gogo can reclaim the 50-day moving average. Above puts $6-plus on the table and a possible retest of channel resistance. If it doesn't, $5 is back on the table. Top Stock Trades for Tomorrow No. 3: Bank of America (BAC)Source: Chart courtesy of StockCharts.comLike Gogo, Bank of America (NYSE:BAC) also displayed relative strength on Monday. In fact, BofA hit a new 52-week high.I have been waiting -- AKA hoping -- for a pullback in BAC stock, as its Q4 breakout has been very impressive. The stock continues to do an excellent job holding onto its recent gains, something many traders have surely noticed.$33 was resistance last week, but holding above it now puts $34-plus on the table. If it falls below $33, let's see if uptrend support and the 20-day moving average can buoy the name.If not, see if buyers step in around $32. Dropping below there could put the 50-day moving average on watch. If we get a real correction in the market, a retest of $30.50 to $31 would be attractive in BAC. Top Stock Trades for Tomorrow No. 4: Bristol-Myers Squibb (BMY)Source: Chart courtesy of StockCharts.comNot to beat the relative-strength theme to death, but Bristol-Myers Squibb (NYSE:BMY) was also on display Monday. Channel support (blue line) held throughout last week, and shares are now trying to push through $58.From here, the setup is straightforward. Either BMY reclaims $58 or it doesn't.If it does, it puts the 52-week high of $59.17 on the table, with channel resistance being the upside target above that. If Bristol-Myers can't reclaim $58, then channel support will again be called on. Should it fail, see if buyers step in near $55 again, while the 50-day moving average should act as support as well.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long GOGO and ROKU. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY appeared first on InvestorPlace.
- Investor's Business Daily
Looking For Growth? Take A Look At These Biotechnology Stocks
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
- Zacks
AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC
AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.
- American City Business Journals
Novartis-linked biotech firm raises $56M for new spinouts
After signing two back-to-back deals with Novartis this year, small Boston-based startup IFM Therapeutics is ramping up its business development with a new incubator.
- Insider Monkey
Is Bristol Myers Squibb Company (BMY) A Good Stock To Buy?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Barrons.com
Don’t Write Off Energy Stocks Yet
Four cheap energy stocks for investors to consider, on the expectation that the increasingly unpopular sector will emerge from a decadelong slump. Plus: a bet on three drugs formerly in Celgene’s pipeline.
- Insider Monkey
Here is the 24th Most Popular Stock Among 752 Hedge Funds
Is Booking Holdings Inc. (NASDAQ:BKNG) a good place to invest some of your money right now? We are going to take a look at hedge fund activity surrounding BKNG as well as its peers like Bristol Myers Squibb Company (NYSE:BMY), CVS Health Corporation (NYSE:CVS), Itau Unibanco Holding SA (NYSE:ITUB), and Fidelity National Information Services Inc. (NYSE:FIS) […]
- Zacks
The Extreme Risks of Trading Your Own Retirement Assets - November 28, 2019
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Investor's Business Daily
Bristol-Myers Squibb Meets 80-Plus Relative Strength Rating Benchmark
Bristol-Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
- Zacks
Top Ranked Income Stocks to Buy for November 27th
Top Ranked Income Stocks to Buy for November 27th
